Prosthetic joint infections - Pipeline Insight, 2021
This report can be delivered to the clients within 24 hours
DelveInsight’s, “Prosthetic joint infections - Pipeline Insight, 2021,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Prosthetic joint infections pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Prosthetic joint infections: Overview
Prosthetic joint infection (PJI), also referred to as periprosthetic infection, is defined as infection involving the joint prosthesis and adjacent tissue. The clinical manifestations of PJI vary depending upon the virulence of the organism, the mode of initiation of infection, the host immune response, the soft tissue structure surrounding the joint, and the joint involved. The diagnosis of PJI is based upon a combination of clinical findings, laboratory results from peripheral blood and synovial fluid, microbiological data, histological evaluation of periprosthetic tissue, intraoperative inspection, and/or radiographic results. Treatment for PJI involves surgical intervention and medical therapy with an aim to eradicate the infection, restore pain-free function of the infected joint, and minimize PJI-related morbidity and mortality for the patient.
'Prosthetic joint infections - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Prosthetic joint infections pipeline landscape is provided which includes the disease overview and Prosthetic joint infections treatment guidelines. The assessment part of the report embraces, in depth Prosthetic joint infections commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Prosthetic joint infections collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Prosthetic joint infections report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Prosthetic joint infections Emerging Drugs
Further product details are provided in the report……..
Prosthetic joint infections: Therapeutic Assessment
This segment of the report provides insights about the different Prosthetic joint infections drugs segregated based on following parameters that define the scope of the report, such as:
Prosthetic joint infections: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Prosthetic joint infections therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Prosthetic joint infections drugs.
Prosthetic joint infections Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Prosthetic joint infections - Pipeline Insight, 2021,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Prosthetic joint infections pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Prosthetic joint infections: Overview
Prosthetic joint infection (PJI), also referred to as periprosthetic infection, is defined as infection involving the joint prosthesis and adjacent tissue. The clinical manifestations of PJI vary depending upon the virulence of the organism, the mode of initiation of infection, the host immune response, the soft tissue structure surrounding the joint, and the joint involved. The diagnosis of PJI is based upon a combination of clinical findings, laboratory results from peripheral blood and synovial fluid, microbiological data, histological evaluation of periprosthetic tissue, intraoperative inspection, and/or radiographic results. Treatment for PJI involves surgical intervention and medical therapy with an aim to eradicate the infection, restore pain-free function of the infected joint, and minimize PJI-related morbidity and mortality for the patient.
'Prosthetic joint infections - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Prosthetic joint infections pipeline landscape is provided which includes the disease overview and Prosthetic joint infections treatment guidelines. The assessment part of the report embraces, in depth Prosthetic joint infections commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Prosthetic joint infections collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Prosthetic joint infections R&D. The therapies under development are focused on novel approaches to treat/improve Prosthetic joint infections.
This segment of the Prosthetic joint infections report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Prosthetic joint infections Emerging Drugs
- TNP 2092: TenNor Therapeutics
- PLG0206: Peptilogics
Further product details are provided in the report……..
Prosthetic joint infections: Therapeutic Assessment
This segment of the report provides insights about the different Prosthetic joint infections drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Prosthetic joint infections
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- Intravitreal
- Subretinal
- Topical
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Prosthetic joint infections: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Prosthetic joint infections therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Prosthetic joint infections drugs.
Prosthetic joint infections Report Insights
- Prosthetic joint infections Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Prosthetic joint infections drugs?
- How many Prosthetic joint infections drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Prosthetic joint infections?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Prosthetic joint infections therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Prosthetic joint infections and their status?
- What are the key designations that have been granted to the emerging drugs?
- TenNor Therapeutics
- Peptilogics
- Armata Pharmaceuticals
- Contrafect
- Osteal Therapeutics
- TNP 2092
- PLG0206
- AP-SA02
- CF-296
- VT-X7
Introduction
Executive Summary
Prosthetic joint infections: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Prosthetic joint infections – DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
TNP 2092: TenNor Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
PLG0206: Peptilogics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Comparative Analysis
AP-SA02: Armata Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Prosthetic joint infections Key Companies
Prosthetic joint infections Key Products
Prosthetic joint infections- Unmet Needs
Prosthetic joint infections- Market Drivers and Barriers
Prosthetic joint infections- Future Perspectives and Conclusion
Prosthetic joint infections Analyst Views
Appendix
Executive Summary
Prosthetic joint infections: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Prosthetic joint infections – DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
TNP 2092: TenNor Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
PLG0206: Peptilogics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Comparative Analysis
AP-SA02: Armata Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Prosthetic joint infections Key Companies
Prosthetic joint infections Key Products
Prosthetic joint infections- Unmet Needs
Prosthetic joint infections- Market Drivers and Barriers
Prosthetic joint infections- Future Perspectives and Conclusion
Prosthetic joint infections Analyst Views
Appendix
LIST OF TABLES
Table 1 Total Products for Prosthetic joint infections
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Prosthetic joint infections
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Prosthetic joint infections
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Prosthetic joint infections
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
